Patents by Inventor James F. Callahan

James F. Callahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,6-dicarba-vasopressin compounds
    Patent number: 4760052
    Abstract: New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.
    Type: Grant
    Filed: April 28, 1987
    Date of Patent: July 26, 1988
    Assignee: Smithkline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Kenneth A. Newlander, Nelson C. F. Yim
  • Methods of producing vasodilation or antioxytocic activity
    Patent number: 4684621
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: April 16, 1986
    Date of Patent: August 4, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Polypeptide intermediates
    Patent number: 4658015
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: April 16, 1986
    Date of Patent: April 14, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Aromatic basic-tailed vasopressin antagonists
    Patent number: 4624943
    Abstract: Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)benzene-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: March 20, 1985
    Date of Patent: November 25, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, Michael L. Moore, Nelson C. Yim
  • Basic V.sub.1 -vasopressin antagonists
    Patent number: 4604378
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: November 21, 1984
    Date of Patent: August 5, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Basic heptapeptide vasopressin antagonists
    Patent number: 4543349
    Abstract: Certain cyclic vasopressin-like peptides, which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have vasopressin antagonist activity. A species of this series of new compounds is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desarginine -9-desglycinamide]-vasopressin.
    Type: Grant
    Filed: August 28, 1984
    Date of Patent: September 24, 1985
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, Michael L. Moore, Nelson C. Yim